Omega Fund VI, L.P. 4
4 · Imago BioSciences, Inc. · Filed Jul 20, 2021
Insider Transaction Report
Form 4
Omega Fund VI, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2021-07-20+492,828→ 3,018,737 total - Conversion
Common Stock
2021-07-20+2,275,909→ 2,525,909 total - Conversion
Series C convertible Preferred Stock
2021-07-20−492,828→ 0 total→ Common Stock (492,828 underlying) - Conversion
Series B convertible Preferred Stock
2021-07-20−2,275,909→ 0 total→ Common Stock (2,275,909 underlying)
Footnotes (2)
- [F1]Each share of the issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) shares of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on July 20, 2021 and had no expiration date.
- [F2]The reported securities are beneficially owned by Omega Fund VI, L.P. ("Omega VI"). The reported securities may be deemed to be beneficially owned by each of Omega Fund VI GP, L.P. ("Omega VI GP"), as the general partner of Omega VI, and Omega Fund VI GP Manager, Ltd. ("Omega VI GP Manager"), as the general partner of Omega VI GP. Otello Stampacchia, Claudio Nessi and Anne-Mari Paster are all the shareholders and directors of Omega VI GP Manager and have shared voting and investment power over the shares held by Omega VI and, as a result, may each be deemed to beneficially own the reported securities. Each of such individuals disclaims beneficial ownership of the shares held by Omega VI.